Multi-institutional analysis of radiation modality use and postoperative outcomes of neoadjuvant chemoradiation for esophageal cancer
Steven H. Lin(The University of Texas MD Anderson Cancer Center), Christopher L. Hallemeier(Mayo Clinic in Arizona), Jincheng Shen(University of Utah), Minesh P. Mehta(Columbia University), Reza J. Mehran(The University of Texas MD Anderson Cancer Center), Ritsuko Komaki(The University of Texas MD Anderson Cancer Center), Neha Bhooshan(University of Maryland, Baltimore), Vivek Verma(Christ University), Michael G. Haddock(Mayo Clinic in Arizona), Lu Wang(Guangzhou University of Chinese Medicine), Zhongxing Liao(Thoracic Surgery Foundation), Kenneth W. Merrell(Mayo Clinic), Sarah E. James(Mayo Clinic), James D. Cox(Washington University in St. Louis), Mohan Suntharalingam(University of Maryland, Baltimore), Peter F. Thall(The University of Texas MD Anderson Cancer Center), Arlene M. Correa(The University of Texas MD Anderson Cancer Center), Michael D. Chuong(Baptist Hospital of Miami)
Cited by 105
Related Papers
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial
|The Lancet|2004|2.4k
Cholangiocarcinoma — evolving concepts and therapeutic strategies
|Nature Reviews Clinical Oncology|2017|1.7k
Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases
|Journal of Clinical Oncology|2011|1.4k
Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402
|Journal of Clinical Oncology|2012|1.2k